Which trial showed that ACE-Is or ARBs are the preferred class of BP-modifying agent in CKD patients with microalbuminuria?
The Work Group suggests ACE-Is or ARBs as the preferred class of BP-modifying agent in CKD patients with microalbuminuria. This recommendation is based on observational data and subgroup and post hoc analyses, hence the grade of 2D.